ECSP10010287A - Vectores de virus oncolíticos de viruela - Google Patents
Vectores de virus oncolíticos de viruelaInfo
- Publication number
- ECSP10010287A ECSP10010287A EC2010010287A ECSP10010287A ECSP10010287A EC SP10010287 A ECSP10010287 A EC SP10010287A EC 2010010287 A EC2010010287 A EC 2010010287A EC SP10010287 A ECSP10010287 A EC SP10010287A EC SP10010287 A ECSP10010287 A EC SP10010287A
- Authority
- EC
- Ecuador
- Prior art keywords
- viruela
- oncolitical
- virus vectors
- compositions
- smallpox
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 241000269781 Zoarcidae Species 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 241000700647 Variola virus Species 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301556 | 2007-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010287A true ECSP10010287A (es) | 2010-08-31 |
Family
ID=40548531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010287A ECSP10010287A (es) | 2007-11-19 | 2010-06-18 | Vectores de virus oncolíticos de viruela |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9180150B2 (enExample) |
| EP (1) | EP2212423B1 (enExample) |
| JP (1) | JP5710262B2 (enExample) |
| KR (1) | KR101542275B1 (enExample) |
| CN (1) | CN101868546B (enExample) |
| AU (1) | AU2008328258B2 (enExample) |
| BR (1) | BRPI0820578A2 (enExample) |
| CA (1) | CA2705873C (enExample) |
| CO (1) | CO6210761A2 (enExample) |
| CR (1) | CR11520A (enExample) |
| DK (1) | DK2212423T3 (enExample) |
| EC (1) | ECSP10010287A (enExample) |
| ES (1) | ES2535633T3 (enExample) |
| HR (1) | HRP20150360T1 (enExample) |
| IL (1) | IL204539A (enExample) |
| MX (1) | MX2010005273A (enExample) |
| NZ (1) | NZ584201A (enExample) |
| PL (1) | PL2212423T3 (enExample) |
| RU (2) | RU2557312C2 (enExample) |
| WO (1) | WO2009065547A2 (enExample) |
| ZA (1) | ZA201004286B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744294A1 (en) | 2009-01-13 | 2010-07-22 | Transgene Sa | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| EP2452194B1 (en) | 2009-07-10 | 2015-11-11 | Transgene SA | Biomarker for selecting patients and related methods |
| WO2013004658A1 (en) | 2011-07-01 | 2013-01-10 | Transgene Sa | Formulations of 5-fluorocytosine and uses thereof. |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| US10517943B2 (en) | 2014-12-01 | 2019-12-31 | Transgene S.A. | Stable liquid vaccinia virus formulations |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| KR20250067190A (ko) * | 2016-08-09 | 2025-05-14 | 시티 오브 호프 | 키메라 폭스바이러스 조성물 및 이의 용도 |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| CA3045228C (en) | 2016-12-28 | 2024-01-02 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| CN111163803B (zh) * | 2017-08-11 | 2025-05-09 | 希望之城公司 | 表达car t细胞靶物的溶瘤病毒及其用途 |
| JP2021511060A (ja) * | 2018-01-26 | 2021-05-06 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| US12698512B2 (en) | 2023-11-06 | 2026-08-04 | City Of Hope | Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| EP1367128A1 (en) * | 1991-03-07 | 2003-12-03 | Connaught Technology Corporation | Genetically engineered vaccine strain |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| AU5446700A (en) * | 1999-05-28 | 2000-12-18 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| US6897057B1 (en) * | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
| MXPA05013879A (es) * | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| DK2212345T3 (en) * | 2007-11-19 | 2016-03-21 | Transgene Sa | Oncolytic poxvirus vectors |
-
2008
- 2008-11-17 EP EP08851361.9A patent/EP2212423B1/en not_active Not-in-force
- 2008-11-17 RU RU2013129678/10A patent/RU2557312C2/ru not_active IP Right Cessation
- 2008-11-17 DK DK08851361T patent/DK2212423T3/en active
- 2008-11-17 AU AU2008328258A patent/AU2008328258B2/en not_active Ceased
- 2008-11-17 PL PL08851361T patent/PL2212423T3/pl unknown
- 2008-11-17 NZ NZ584201A patent/NZ584201A/en not_active IP Right Cessation
- 2008-11-17 ES ES08851361.9T patent/ES2535633T3/es active Active
- 2008-11-17 KR KR1020107010821A patent/KR101542275B1/ko not_active Expired - Fee Related
- 2008-11-17 WO PCT/EP2008/009721 patent/WO2009065547A2/en not_active Ceased
- 2008-11-17 MX MX2010005273A patent/MX2010005273A/es active IP Right Grant
- 2008-11-17 BR BRPI0820578-7A patent/BRPI0820578A2/pt not_active Application Discontinuation
- 2008-11-17 CA CA2705873A patent/CA2705873C/en not_active Expired - Fee Related
- 2008-11-17 HR HRP20150360TT patent/HRP20150360T1/hr unknown
- 2008-11-17 US US12/743,412 patent/US9180150B2/en not_active Expired - Fee Related
- 2008-11-17 RU RU2010124613/10A patent/RU2508401C2/ru not_active IP Right Cessation
- 2008-11-17 JP JP2010533511A patent/JP5710262B2/ja not_active Expired - Fee Related
- 2008-11-17 CN CN2008801168337A patent/CN101868546B/zh not_active Expired - Fee Related
-
2010
- 2010-03-16 IL IL204539A patent/IL204539A/en active IP Right Grant
- 2010-06-17 ZA ZA2010/04286A patent/ZA201004286B/en unknown
- 2010-06-18 EC EC2010010287A patent/ECSP10010287A/es unknown
- 2010-06-18 CO CO10073787A patent/CO6210761A2/es not_active Application Discontinuation
- 2010-06-18 CR CR11520A patent/CR11520A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010288A (es) | Vectores de virus oncolíticos de viruela | |
| CR11520A (es) | Vectores de virus oncoliticos de viruela | |
| MX2013002207A (es) | Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13. | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
| GT201400230A (es) | Necleòsidos de espìrooxetano de uracilo | |
| BR112019024813A2 (pt) | adenovírus recombinantes portando transgenes | |
| CY1121450T1 (el) | Θεραπεια συνδυασμου για θεραπεια καρκινου | |
| PY1337526A (es) | Métodos para tratar o prevenir asma administrando un antagonista de IL-4R. | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| GT201400097A (es) | Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
| NI201200175A (es) | Métodos de tratamiento de cáncer de vejiga | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| BR112016012358A2 (pt) | peptídios terapêuticos | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| EA201591402A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
| ECSP11011054A (es) | Péptidos antivirales terapéuticos | |
| CR20110553A (es) | Terapia complementaria contra el cáncer | |
| BR112014013374A2 (pt) | formulações de acamprosato, métodos de usar o mesmo, e as combinações que compõem o mesmo |